{
    "clinical_study": {
        "@rank": "3263", 
        "arm_group": [
            {
                "arm_group_label": "NGM282 Dose 1", 
                "arm_group_type": "Experimental", 
                "description": "NGM282 Dose 1"
            }, 
            {
                "arm_group_label": "NGM282 Dose 2", 
                "arm_group_type": "Experimental", 
                "description": "NGM282 Dose 2"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the safety, tolerability, and activity of NGM282\n      in patients with Primary Biliary Cirrhosis."
        }, 
        "brief_title": "Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Primary Biliary Cirrhosis", 
        "condition_browse": {
            "mesh_term": [
                "Liver Cirrhosis, Biliary", 
                "Liver Cirrhosis", 
                "Fibrosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males or females, between 18 and 75 years of age, inclusive\n\n          -  PBC diagnosis consistent with AASLD and EASL guidelines\n\n          -  Stable dose of UDCA\n\n        Exclusion Criteria:\n\n          -  Chronic liver disease of a non-PBC etiology\n\n          -  Evidence of clinically significant hepatic decompensation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02026401", 
            "org_study_id": "13-0103"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "NGM282 Dose 1", 
                    "NGM282 Dose 2"
                ], 
                "intervention_name": "NGM282", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 20, 2014", 
        "link": {
            "url": "http://www.ngmbio.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan"
                    }, 
                    "name": "NGM Clinical Study Site 101"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sydney", 
                        "country": "Australia", 
                        "state": "New South Wales"
                    }, 
                    "name": "NGM Clinical Study Site 602"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sydney", 
                        "country": "Australia", 
                        "state": "New South Wales"
                    }, 
                    "name": "NGM Clinical Study Site 603"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sydney", 
                        "country": "Australia", 
                        "state": "New South Wales"
                    }, 
                    "name": "NGM Clinical Study Site 611"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sydney", 
                        "country": "Australia", 
                        "state": "New South Wales"
                    }, 
                    "name": "NGM Clinical Study Site 609"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sydney", 
                        "country": "Australia", 
                        "state": "New South Wales"
                    }, 
                    "name": "NGM Clinical Study Site 606"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brisbane", 
                        "country": "Australia", 
                        "state": "Queensland"
                    }, 
                    "name": "NGM Clinical Study Site 614"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Adelaide", 
                        "country": "Australia", 
                        "state": "South Australia"
                    }, 
                    "name": "NGM Clinical Study Site 607"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Adelaide", 
                        "country": "Australia", 
                        "state": "South Australia"
                    }, 
                    "name": "NGM Clinical Study Site 608"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Melbourne", 
                        "country": "Australia", 
                        "state": "Victoria"
                    }, 
                    "name": "NGM Clinical Study Site 601"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Melbourne", 
                        "country": "Australia", 
                        "state": "Victoria"
                    }, 
                    "name": "NGM Clinical Study Site 613"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Melbourne", 
                        "country": "Australia", 
                        "state": "Victoria"
                    }, 
                    "name": "NGM Clinical Study Site 605"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Melbourne", 
                        "country": "Australia", 
                        "state": "Victoria"
                    }, 
                    "name": "NGM Clinical Study Site 604"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Pharmacodynamic Activity of NGM282 in Combination With Ursodeoxycholic Acid (UDCA) Administered for 28 Days in Patients With Primary Biliary Cirrhosis", 
        "overall_contact": {
            "email": "melliott@ngmbio.com", 
            "last_name": "Michael Elliott", 
            "phone": "650-243-5571"
        }, 
        "overall_official": {
            "affiliation": "NGM Biopharmaceuticals, Inc", 
            "last_name": "Stephen J Rossi, PharmD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Australia: Department of Health and Ageing Therapeutic Goods Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Absolute change in plasma ALP from Baseline to Day 28", 
            "safety_issue": "No", 
            "time_frame": "28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02026401"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Absolute change in bilirubin from Baseline to Day 28", 
            "safety_issue": "No", 
            "time_frame": "28 days"
        }, 
        "source": "NGM Biopharmaceuticals, Inc", 
        "sponsors": {
            "collaborator": {
                "agency": "NGM Biopharmaceuticals Australia Pty Ltd", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "NGM Biopharmaceuticals, Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}